Drug intelligence / Profile preview

AKG-220

Development stage: Preclinical
Lead developer: Akagera Medicines
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

AKG-220 is an investigational mRNA-based prophylactic vaccine being developed by Akagera Medicines for the prevention of Lassa Fever. Utilizing messenger RNA technology, the vaccine is designed to deliver genetic instructions to cells to produce viral antigens, thereby stimulating a protective immune response against the Lassa virus. AKG-220 is currently in the preclinical stage of development as part of Akagera's infectious disease vaccine pipeline, which focuses on addressing high-burden global health threats.

Other names: Akagera Lassa fever mRNA vaccineligand-directed mRNA-LNP Lassa fever vaccine

Targets

Lassa virus antigens

Beyond the preview

Go deeper on AKG-220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKG-220.

Explore the full profile